COP vs REGN
ConocoPhillips (COP) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
ConocoPhillips (COP) is a oil & gas e&p company listed on NYSE. It is led by Ryan Lance.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported COP revenue for 2025-12-31 was $58.94B. Net income was $7.99B. Revenue was up 7.7% from 2024-12-31 to 2025-12-31. COP currently screens at market cap $135.49B and trailing P/E 18.8.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
COP currently screens at market cap $135.49B and trailing P/E 18.8. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the COP and REGN stock pages for the full models.
Not investment advice.